View in EDS

POSB16 Overall Survival Indirect Treatment Comparison Results Adjusted for Treatment Crossover: Brigatinib Relative to Alectinib in Patients with ALK+ NSCLC Previously Untreated with an ALK Inhibitor Using the Final Results from Alta-1L and Alex.

Saved in:
Bibliographic Details
Title: POSB16 Overall Survival Indirect Treatment Comparison Results Adjusted for Treatment Crossover: Brigatinib Relative to Alectinib in Patients with ALK+ NSCLC Previously Untreated with an ALK Inhibitor Using the Final Results from Alta-1L and Alex.
Authors: Cranmer, H1 (AUTHOR), Lin, HM2 (AUTHOR), Kay, S3 (AUTHOR), Cazzato, S4 (AUTHOR)
Source: Value in Health. 2022 Supplement, Vol. 25 Issue 1, pS27-S27. 1p.
Database: Academic Search Ultimate
FullText Text:
  Availability: 0
Header DbId: asn
DbLabel: Academic Search Ultimate
An: 154761446
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: POSB16 Overall Survival Indirect Treatment Comparison Results Adjusted for Treatment Crossover: Brigatinib Relative to Alectinib in Patients with ALK+ NSCLC Previously Untreated with an ALK Inhibitor Using the Final Results from Alta-1L and Alex.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Cranmer%2C+H%22">Cranmer, H</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lin%2C+HM%22">Lin, HM</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kay%2C+S%22">Kay, S</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cazzato%2C+S%22">Cazzato, S</searchLink><relatesTo>4</relatesTo> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Value+in+Health%22">Value in Health</searchLink>. 2022 Supplement, Vol. 25 Issue 1, pS27-S27. 1p.
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=154761446
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jval.2021.11.126
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 1
        StartPage: S27
    Titles:
      – TitleFull: POSB16 Overall Survival Indirect Treatment Comparison Results Adjusted for Treatment Crossover: Brigatinib Relative to Alectinib in Patients with ALK+ NSCLC Previously Untreated with an ALK Inhibitor Using the Final Results from Alta-1L and Alex.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Cranmer, H
      – PersonEntity:
          Name:
            NameFull: Lin, HM
      – PersonEntity:
          Name:
            NameFull: Kay, S
      – PersonEntity:
          Name:
            NameFull: Cazzato, S
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 01
              Text: 2022 Supplement
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 10983015
          Numbering:
            – Type: volume
              Value: 25
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Value in Health
              Type: main
ResultId 1